Consumer Insecurity / Vanity Targeted by TGA – Massive Fines

The Federal Court imposes $10 million penalty for the alleged Peptide Clinics advertising breaches. Peptide Clinics Pty Ltd was liquidated earlier this year.

The appearance of misleading terms and claims on websites and social media has attracted the attention of the TGA.

The  Therapeutic Goods Administration in Australia (TGA) has advised that fines were imposed via the Federal Court for misleading advertising by Peptide Clinics Australia (Peptide Clinics Pty Ltd), to the tune of $10 million (for breaches of advertising prescription-only medicines to the public).

$10 million penalty ordered against Peptide Clinics Pty Ltd for advertising breaches!

Today the Federal Court ordered that Peptide Clinics Australia (Peptide Clinics Pty Ltd) pay $10 million to the Commonwealth for breaches of the mandatory rules for advertising of medicines, including the ban on advertising prescription-only medicines to the public.

The substantial penalties imposed reflect the very real dangers to public health and safety and the appalling conduct of Peptide Clinics. This was particularly due to the clinic giving the impression that medical practitioners were involved in the business, misleading consumers to think that those practitioners were acting in their best interests.

Australian Government, Department of Health, Therapeutic Goods Administration

We’ve talked about compliance in  Advertising Therapeutic Goods in Australia  before but this dollar figure and what led to the fine, are worth exploring in more detail.

The specific issues included advertising Schedule 4 substances (prescription only medicines) on the company’s website and on social media channels, advertisements using the word “peptides”, advertising prohibited and restricted representations, and more.

Peptide Clinics Advertising Breaches

The Federal Court accepted the Secretary’s submission that Peptide Clinics – deliberately and recklessly pursued its own financial self-interest at the expense of its legal obligations and the interests to the health of the public.

The responsibility of product Sponsors in Australia is to ensure that their advertising is –

  • Truthful
  • Balanced
  • Not misleading or likely to mislead, including in its claims, presentations, representations and comparisons.

Use of words that consumers do not understand like ‘peptides’ or specific diseases that require proper diagnosis by a registered health professional (such as cancer or arteriosclerosis are not allowed.

Also, reference to areas related to consumer insecurity and vanity such as anxiety, anti-ageing, body-building, tanning, weight loss, premature ejaculation, hair loss and insomnia relief, were called out as areas of concern for TGA.

This civil court proceeding and the potential for criminal offences and jail time are just not worth the risk to you or your business. 

Adjutor Healthcare Pty Ltd , offers a range of services for prescription and medical device clients to ensure that they comply with the Therapeutic Goods Act as well as the Therapeutic Goods Advertising Code and recent updates.

Through our associates internationally, we also ensure advertising compliance in excess of 90 countries.

If you would like training, guidance or assistance with compliance in advertising, please contact us for a confidential discussion.

More recent articles

  • Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…

  • Australia’s TGA Priority Review Pathway

    Australia’s TGA Priority Review Pathway

    How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…